Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
Stockhouse7d
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
On September 18, 2024, it was reported that Novo was agreeing to pay NanoVation Therapeutics up to $600 million, plus research funding in addition to tiered royalties to collaborate on up to seven ...
PopVax Announces 1.15 Million USD in Funding from the Bill and Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
BusinessWire India Mumbai Maharashtra Hyderabad Telangana [India] October 30 PopVax an Indian full-stack biotechnology ...
Nasdaq17d
Top 4 Canadian Biotech Stocks of 2024
Trials for the candidate are advancing. On July 8, the company entered into a collaborative agreement with NanoVation Therapeutics, a biotech company that develops customized nucleic acid and ...
Business Wire14d
PopVax Announces 1.15 Million USD in Funding from the Bill and Melinda Gates Foundation for Thermostable mRNA Delivery Formulation Development
who previously worked with pioneering nucleic acid delivery research groups at NanoVation Therapeutics and during his PhD at the University of British Columbia in Canada. “We at PopVax are ...